Document is current
Any future updates will be listed below
-
Authors
Unterholzner, Jakob
Kautzky, Alexander https://orcid.org/0000-0001-9251-8285
Reed, Murray Bruce
Wechsler, Theresa Friederike https://orcid.org/0000-0001-5514-2311
Popper, Valentin
Spurny-Dworak, Benjamin
Stöhrmann, Peter https://orcid.org/0000-0002-7324-0414
Klöbl, Manfred https://orcid.org/0000-0003-2107-8803
Varghese, Nimmy
Mühlberger, Andreas
Eckert, Anne https://orcid.org/0000-0002-9341-3669
Frey, Richard
Rujescu, Dan https://orcid.org/0000-0002-1432-313X
Lanzenberger, Rupert https://orcid.org/0000-0003-4641-9539
Vanicek, Thomas https://orcid.org/0000-0002-5116-9899
-
Funding
Funding for this research was provided by:
Magistrat der Stadt Wien (APCOV26BGM)
- License Information
-
More Information
Article History
Received: 2 June 2023
Revised: 19 December 2023
Accepted: 2 January 2024
First Online: 19 January 2024
Competing interests
: RL received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. JU received travel grants from Medice Pharma GmbH. TV received speaker honoraria from Janssen. DR served as consultant for Janssen, received honoraria from Gerot Lannacher, Janssen and Pharmagenetix, received travel support from Angelini and Janssen, and served on advisory boards of AC Immune, Roche and Rovi. AK, MBR, TFW, PV, BSD, PS, MK, NV, AM, AE and RF declare no conflict of interests.
